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Abstract
Background: Current histo-pathological prognostic factors are not very helpful in predicting the
clinical outcome of breast cancer due to the disease's heterogeneity. Molecular profiling using a
large panel of genes could help to classify breast tumours and to define signatures which are
predictive of their clinical behaviour.
Methods: To this aim, quantitative RT-PCR amplification was used to study the RNA expression
levels of 47 genes in 199 primary breast tumours and 6 normal breast tissues. Genes were selected
on the basis of their potential implication in hormonal sensitivity of breast tumours. Normalized
RT-PCR data were analysed in an unsupervised manner by pairwise hierarchical clustering, and the
statistical relevance of the defined subclasses was assessed by Chi2 analysis. The robustness of the
selected subgroups was evaluated by classifying an external and independent set of tumours using
these Chi2-defined molecular signatures.
Results: Hierarchical clustering of gene expression data allowed us to define a series of tumour
subgroups that were either reminiscent of previously reported classifications, or represented
putative new subtypes. The Chi2 analysis of these subgroups allowed us to define specific molecular
signatures for some of them whose reliability was further demonstrated by using the validation data
set. A new breast cancer subclass, called subgroup 7, that we defined in that way, was particularly
interesting as it gathered tumours with specific bioclinical features including a low rate of
recurrence during a 5 year follow-up.
Conclusion: The analysis of the expression of 47 genes in 199 primary breast tumours allowed
classifying them into a series of molecular subgroups. The subgroup 7, which has been highlighted
by our study, was remarkable as it gathered tumours with specific bioclinical features including a
low rate of recurrence. Although this finding should be confirmed by using a larger tumour cohort,
it suggests that gene expression profiling using a minimal set of genes may allow the discovery of
new subclasses of breast cancer that are characterized by specific molecular signatures and exhibit
specific bioclinical features.
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Background
Breast cancer is the most common female cancer in the
Western world and the leading cause of death by cancer
among women [1]. It is a complex genetic disease charac-
terized by an accumulation of molecular alterations
resulting in an important clinical heterogeneity. Current
prognostic factors (including lymph node status, tumour
size, histological grade, hormone receptor status, ERBB2
expression and patient age) are insufficient to accurately
predict the clinical outcome. High-throughput molecular
technologies, including large-scale RT-PCR and cDNA
microarrays, have made possible to study the gene expres-
sion profiles of tumours. Unsupervised analysis of data by
hierarchical clustering allows grouping tumours on the
basis of similarities in their gene expression patterns. Sam-
ples that share molecular profiles might be expected to
share phenotypic features, such as those that can define
the severity of the disease. Hierarchical clustering of gene
expression patterns has been successfully used to identify
subtypes of breast tumours that exhibit distinct clinical
behaviours [2-6]. At least five subtypes (luminal A, lumi-
nal B, basal-like, ERBB2, and normal-like) have been
identified on the basis of the pattern of expression of a
500-gene set. The luminal A and luminal B subtypes
gather ER+ tumours, while the basal-like, ERBB2 and nor-
mal-like subclasses assemble ER- tumours. Interestingly,
the luminal subtype A exhibits a relatively good progno-
sis, while the luminal B tumours present a worse progno-
sis. The basal-like and ERBB2 subsets show the worst
clinical outcome [3,4]. This molecular classification has
been confirmed using extended or different tumour sets
[4], as well as partly distinct or reduced gene sets [4-6].
Noteworthy, a similar taxonomy of breast cancers has
been characterized using immunohistochemistry [7-9],
although further work seems necessary to correlate the
respective subtypes at mRNA and protein expression lev-
els.
However, more than 30% of the 295 breast tumours,
which have been used to identify and validate the 70-gene
good prognosis signature [10,11], could not be confi-
dently assigned to any of the five subtypes defined so far
[12]. Such an inability to classify all breast cancers in the
five molecular subtypes may be due to an incomplete rep-
resentation of the genes used for the intrinsic set of genes
(when compared to the initial one) or, alternatively, to
the distinct nature of the tumours used in the different
studies. In any case, this failure suggests that other molec-
ular subclasses are waiting for characterization.
In the present study, we have classified 199 primary breast
tumours and 6 normal breast tissues based on the expres-
sion of 47 genes that had been selected on the basis of
their possible involvement in breast tumour hormonal
sensitivity. Gene expression was evaluated by measuring
levels of specific mRNAs using quantitative RT-PCR. Fol-
lowing hierarchical clustering and Chi2 analysis of the
expression data, we defined a series of molecular breast
cancer subgroups that were characterized by specific
molecular signatures. They are either reminiscent of those
previously reported, or represent putative new subclasses.
One of the subtypes, which we defined, gathered tumours
with specific bioclinical features including a low rate of
recurrence within a 5 year follow-up.
Methods
Patients and breast tissue samples
A total of 199 primary breast carcinomas and 6 normal
breast tissues were analysed in this study. They were
obtained from patients who had undergone initial surgery
at the Cancer Research Centre Val d'Aurelle-Paul
Lamarque in Montpellier. All tumours were from patients
who did not receive neo-adjuvant treatment. The patients'
age at diagnosis varied from 27 to 92 years (mean 63
years, median 65 years). All but 1 patient were treated
with one or more adjuvant therapies (Additional File 1,
Table S1). This study was conducted under the approval of
the Institutional Review Board of the Cancer Research
Centre Val d'Aurelle-Paul Lamarque. Informed consent
was obtained from the patients prior to surgery. For the
199 patients, the median follow-up time was 65.4
months. Recurrence was observed in 34 patients (27 dis-
tant and 5 local recurrences, 2 not determined). The
median recurrence time was 32.3 months.
Fresh tissues were processed immediately after surgical
removal. One part of each tumour was formalin-fixed and
paraffin-embedded to establish the histological type (139
ductal and 35 lobular carcinomas, 10 mixed ductal/lobu-
lar carcinomas and 15 other types; Additional File 1, Table
S2) and the histological grade (WHO classification: 16%
SBR I, 55% SBR II and 26% SBR III tumours; Additional
File 1, Table S3). Lymph nodes were also available (38%
patients were N+ at the time of diagnosis, Additional File
1, Table S3). The remaining of each tumour was snap-fro-
zen in liquid nitrogen and stored at -80C. Frozen sections
were stained with Haematoxylin and Eosin and analysed
by an experienced breast pathologist. Eligible samples had
to consist of at least 50% of tumour cells. ER status was
determined by using ligand-binding assay (the ER positiv-
ity threshold was ≥ 10 fmol/mg).
RNA extraction and purification
Frozen breast samples were homogenized using the Fast-
Prep System from Q-Biogene. Briefly, approximately 40
mg of frozen tissues were broken up in lysing buffer on a
lysing matrix for 40 sec. Total RNA was extracted and
cleaned up from the lysate using the Qiagen Rneasy Mini
Kit. The RNA purity and integrity was controlled by way ofBMC Cancer 2007, 7:39 http://www.biomedcentral.com/1471-2407/7/39
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the Bioanalyser 2100 from Agilent. Only RNAs with a
score 8–10 were included in this study.
cDNA synthesis
After DNAse treatment, 1 μg of total RNA was incubated
with 250 ng of random hexamer for 10 min at 70°C. Total
RNA was reverse transcribed in a final volume of 20 μl
containing 1× first strand buffer, 0.1 M DTT, 10 mM dNTP
and 200 units of Superscript RT. The samples were incu-
bated at 25°C for 10 min, and then at 42°C for 1 h. The
reverse transcriptase was finally inactivated by heating at
70°C for 15 min.
PCR amplification
Primers of the selected genes were designed using the
Primer Express software (PE Applied Biosystems), based
on published sequences, and oligonucleotides were
obtained from Proligo.
For quantitative RT-PCR, 2 μl of diluted RT-reaction sam-
ples (1/15) were added to 13 μl of a PCR mixture made up
of 7.5 μl of 2× SYBR Green PCR Master Mix (Applied Bio-
systems), 0.075 μl of each primer at a concentration of
100 μM and RNAse-free water. The thermal cycling condi-
tions comprised an initial step at 50°C for 2 min and a
denaturation step at 95°C for 10 min, followed by 40
cycles at 95°C for 15 sec and 60°C for 1 min. All PCR
reactions were carried out using an ABI Prism 7000
Sequence Detection System (Applied Biosystem). The spe-
cificity of each primer couple was demonstrated by a dis-
sociation curve analysis. To generate a calibration curve, a
serially diluted cDNA mixture was used as standard and
quantified for each primer set. The standard concentration
was plotted against the cycle number at which the fluores-
cence signal increased above the background (threshold)
value (Ct value). The amplification efficiency, E (%) =
(10(1/-s)-1)*100 (s = slope), of each standard curve was
determined and appeared to be > 95% and < 105%, over
a wide dynamic range.
Unsupervised hierarchical clustering of the Q-RT-PCR 
data
The 205 breast samples were distributed in three separate
96-well blocks, according to the time of sample process-
ing. For each experimental sample, the amount of the
gene of interest and of 28S, the endogenous reference, was
determined from the appropriate standard curve in inde-
pendent experiments. Measurements were performed in
duplicate for each data point and those with a coefficient
of variation for the Ct value > 0.5 were tested again. We
calculated the relative fold-change using the comparative
cycle times (Ct) method with 28S as a reference. The
expression value of each gene in each tumour sample was
normalised to the mean expression value for that gene in
all the samples in the block in such a way that each block
had the same overall expression value for one given gene.
Unsupervised analysis of the data was applied to investi-
gate the relationships among genes and among samples.
Hierarchical pairwise average-linkage clustering was per-
formed by means of the Cluster and TreeView software
[13], using Log2-transformed data, median-centered gene
expression values and Pearson correlation as similarity
metrics.
Chi2 statistical analysis
The classification parameter, which was chosen to assess
the statistical relevance of the subgroups defined by hier-
archical clustering, was based on the threshold values of
gene expression. Theoretically, for each relevant gene, all
the samples from one subgroup and those from the others
should be, respectively, below or above a defined thresh-
old. The optimal threshold, which allowed the best dis-
crimination, was defined by a Chi2 analysis.
Firstly, we transformed continuous variables (i.e. gene
expression intensities) into discrete variables (i.e. number
of tumours belonging to a gene expression class, for each
gene and for each tumour subgroup). Gene expression
classes were set from -4 to +5 by step of 0.1. Then, the
Chi2 values were calculated for each of these classes and
for each tumour subgroup as indicated in Table 1.
The highest Chi2 among the different classes for each
tumour subgroup was used to define the thresholds in
order to best discriminate a tumour subgroup from
another. The gene-threshold couple was considered able
to discriminate one class from the others with a good sta-
tistical accuracy, when the corresponding Chi2 value was
≥ 15 (p value ≤ 10-4). Thus, to optimize the test and to cut
Table 1: Chi2 value calculation
Subgroup k Other subgroups
Number of tumours with gene j expression ≥ threshold value O11 O12
Number of tumours with gene j expression ≤ threshold value O21 O22
Chi2 = N*(O11*O22-O12*O21)2/(O11+O21)*(O12+O22)*(O11+O12)*(O21+O22), with:
N = total number of tumours = O11+O12+O21+O22
O11 = number of tumours from class k whose gene j expression level was ≥ threshold value...BMC Cancer 2007, 7:39 http://www.biomedcentral.com/1471-2407/7/39
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the noise, only Chi2 values ≥ 15 as well as the lowest and
highest thresholds among the different subgroups were
considered (Additional File 1, Table S4).
By doing so, a molecular signature was assigned to each
tumour subgroup. A molecular signature was composed
by the genes selected by the Chi2 test with each gene asso-
ciated to an expression threshold. In that way, each sub-
group was characterized by the expression levels of the
signature-genes that specify that subgroup. A tumour was
classified into the subgroup where its gene expression pro-
file followed the thresholds defined in the signature. For
each gene, which specifies one given subgroup, a score of
1 (vs 0) was attributed when the expression level of that
gene was related to the one found to be characteristic of
the subgroup; the tumour was classified into a given sub-
group when the cumulative score observed for the differ-
ent signature genes was found to be the highest. The
robustness of the subgroup was evaluated by the percent-
age of tumours that were correctly classified according to
the defined signatures.
The validation data set
To further validate these molecular subtypes, we used an
external and independent tumourset, which included 97
tumours from the van't Veer et al. [10] and 12 tumours
from the Sorlie et al.'s [4] microarray studies (Additional
File 1, Table S5). These tumours were selected on the basis
of the availability of expression data concerning the 47-
gene set. In order to allow comparison between the Q-RT-
PCR and the microarray data, the two data sets were
median-centered independently. The thresholds for the
analysis of the microarray data were defined as corre-
sponding to those used for the Q-RT-PCR data analysis by
using the QQ plots. We calculated quantile values for the
Q-RT-PCR and microarray data (from the 1st percentile to
the 100th percentile by step of 5%). Then, we set a func-
tion that linearly interpolated the quantile distributions.
Using this function, given a Q-RT-PCR threshold, we
could determine the corresponding microarray threshold.
In the validation set, each tumour was assigned to one of
the previously defined subgroups on the basis of the high-
est score it obtained through the different subgroups.
Results
Gene set selection
We selected 47 candidate genes from the published litter-
ature and genomic databases. Most of these genes (see
Additional File 1, Table S6, for the list of genes and their
accession numbers) were chosen as likely to be involved
in breast tumour sensitivity to steroid hormones. They
included ERα target genes, which are either up- or down-
regulated by oestrogen (Table 2), genes that specify the
already reported breast cancer molecular subtypes (i.e.
luminal, basal, normal-like and ERBB2), and genes that
have been previously shown to be involved in sensitivity
to the anti-oestrogen tamoxifen. As ERα activity has been
shown to be regulated by cross-signalling with growth fac-
tor transduction pathways, we included also growth factor
receptor and signalling genes. Moreover, the selected gene
set also included some putative stem cell markers and
genes coding for cell cycle regulators, because these genes
are believed to contribute to tumor aggressiveness. We
hypothesized that our selected set of genes would allow
discriminating tumours according to both their hormone-
susceptibility and aggressiveness. We hoped that by clus-
tering tumours on the basis of the expression of these
genes we could define new breast cancer subtypes.
Hierarchical clustering of the gene expression profiles
Expression of the 47 genes was assessed by Q-RT-PCR
amplification in the 199 breast tumours and 6 normal
breast tissues. Normalized data were analysed in an unsu-
pervised manner using a pairwise hierarchical clustering
[13]. We used this classical approach to obtain a general
description of how the selected genes co-varied with
respect to their expression levels within the breast tumour
population [14]. Thus, we determined 12 molecular sub-
groups that were characterized by a relative over-expres-
sion or under-expression of distinct combinations of
genes (Figure 1). We limited the number of subclasses to
avoid groups with too few samples that could hinder the
reliability of any classification.
To assess the reliability of the clustering, we computed an
average expression profile (i.e. a core subtype profile) for
the tumours in each of the selected subgroups as per-
formed by Sorlie and co-workers [3]. We calculated the
Pearson's correlation of each sample to each of the 12 core
subtype profiles. As illustrated on Figure S1 (Additional
File 2), for more than 75% of the tumours, the correlation
was the highest with the expression profile of the sub-
group containing that sample, stressing the relevance of
the defined subgroups. At least four subgroups (sub-
groups 6, 7, 9 and 10) appeared to be highly homogene-
ous since most of their tumors showed a correlation of 0.6
to 0.8 with their average subgroup profile.
Some of these subgroups were reminiscent of groups that
have been previously reported [2-6]. For example, sub-
group 10 gathered breast tumours in which the GSTP1
and SERPINB5/maspin as well as the MAD2L1 and MYC
genes, which specify basal-type adenocarcinomas, were
over-expressed (Figure 1). Moreover, in these tumours,
genes, which have been shown to be over-expressed in
luminal-type breast tumours [3,4] (see below), were
under-expressed. Subgroup 9 comprised tumours that
belonged very likely to the ERBB2-like subtype, as they
overexpressed the ERBB2 and GRB7 genes. Interestingly,
in subgroup 6, the 6 normal breast tissues (called CP)BMC Cancer 2007, 7:39 http://www.biomedcentral.com/1471-2407/7/39
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Unsupervised analysis of the Q-RT-PCR expression data by pairwise hierarchical clustering Figure 1
Unsupervised analysis of the Q-RT-PCR expression data by pairwise hierarchical clustering. 12 distinct subclasses 
were defined from the observed gene clusters. The luminal A/B, normal-like, ERBB2 and basal tumour subsets were identified 
according to gene expression signatures that have been previously reported to specify these molecular subtypes [2-4]. Sub-
groups 7 (SG7) and 12 (SG12) are also indicated.
12 3 4 56 78 9 1 0 11 12
ERBB2 Basal SG7 Normal-like Luminal A/B SG12
Table 2: Functional classes of the 47 selected genes
Functional class Genes
Steroid hormone receptors and homologs ESR1, ESR2, PR, ERRA, ERRG, RXRA
ERα target genes
œstrogen up-regulated AREG, BCL2, CCND1, HDAC6, IGF1, IGFBP4, IRS1, KRT19, LIV1, MTA3, MYC PR, TFF1/pS2, TSK/E2IG4
œstrogen down-regulated ABCC5, GSTP1, SERPINB5/maspin
ERRα target genes ACADM, TFF1/pS2, SPP1
ERs/ERRs regulators NCOA3/AIB1, NCOR1, PGC1A
Genes specifying molecular subtypes
luminal A BCL2, ESR1, GATA3, KRT19, LIV1, TFF1/pS2
luminal B/C MYBL2
basal GSTP1, MAD2L1, MYC, SERPINB5/maspin
ERBB2 ERBB2, GRB7
normal-like IGF1, PGC1A
Genes involved in tamoxifen responsiveness AKT2, CCND1, CDKN1B, EPHA2, ESR2, HDAC6, IRS1, NCOA3, NCOR1, PR, PRKAR1A, PTEN
Growth factor receptor and signaling genes AKT2, EPHA2, ERBB2, ERBB4, IGF1R, IRS1, PTEN
Cell cycle genes CCND1, CDK4, CDKN1B, E4F1, MAD2L1
Stem cells markers ABCG2, BMI1, EZH2
Others PTGS2/COX2, TACC1, ZNF217
Genes are indicated in bold characters when present in an extra family.BMC Cancer 2007, 7:39 http://www.biomedcentral.com/1471-2407/7/39
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clustered together with a group of tumours that overex-
pressed IGF1, a feature which is characteristic of normal-
like tumours. In contrast to previous reports, where other
sets of genes were used [3,5,6], we were unable to clearly
discriminate between luminal A and luminal B subtypes.
Indeed, ER+ tumours were scattered in subgroups 1 to 4
that are characterised by the over-expression of a cluster of
genes, which includes CCND1,  KRT19,  IGF1R,  LIV1,
ESR1, GATA3, TFF1/pS2, ERBB4, PR and IGFBP4.
On the other hand, our 47-genes set allowed us to define
new molecular subclasses, such as the subgroups 7 and
12. Subgroup 12 was characterized by the up-regulation of
the PTEN, PRKAR1A, HDAC6 and AKT2 genes, while sub-
group 7 showed down-regulation of two groups of genes:
the first one was constituted by the four genes cited above
with the addition of NCOA3, ABCC5, NCOR1 and E4F1;
the second included GRB7,  ERRA,  EZH2,  MAD2L1,
MYBL2, MYC and SPP1.
Chi2 analysis of the identified breast cancer subgroups
To assess the statistical relevance of the molecular sub-
groups as defined by the hierarchical clustering, we per-
formed a Chi2 analysis of the data (see Methods). This
analysis allowed us to identify genes that were differen-
tially expressed in one subgroup compared to the others
and, therefore, to define a specific molecular signature for
each subgroup.
As shown in Table 3, such specific molecular signatures
could be assigned to 9 of the 12 previously defined sub-
groups. The genes of these specific signatures overlapped
with the ones defined by the hierarchical clustering anal-
ysis. For example, among the 11 down-regulated genes of
the signature of subgroup 10 (Table 3), 8 have been
already observed in the cluster of down-regulated genes
defined by the hierarchical clustering (namely IGF1R,
LIV1, ESR1, GATA3, TFF1/pS2, ERBB4, PR and IGFBP4, see
Figure 1). Also, the 6 genes, which specify subgroup 7,
included 5 under-expressed genes (ABCC5, AKT2, EZH2,
HDAC6 and PRKAR1A) that had been identified before by
the hierarchical classification of the expression data (Fig-
ure 1).
The robustness of each subgroup was evaluated by the
percentage of tumours in that subgroup that were cor-
rectly classified according to the defined molecular signa-
ture. As shown in Table 4, subgroups 2, 3, 7, 9 and 10
formed the most robust groups with over 80% of the
tumours in each group showing the proper signature. Sub-
groups 1, 5 and 6 were found to be slightly weaker (with
about 60–70% of tumours showing the specific signa-
ture). Subgroup 12 was found to be much less significant
with only 43% of tumours classified correctly. Finally, a
definitive molecular signature could not be assigned to
subgroups 4, 8 and 11. However, a high proportion of
tumours from group 4 (approximately 40%) exhibited the
molecular signature that specified subgroup 3. Conse-
quently, we decided to bring together subgroups 3 and 4
for the rest of the study.
External validation of the molecular subgroups
To further validate these molecular subtypes, we used an
external and independent dataset that included 97 from
the van't Veer [10] and 12 tumours from the Sorlie's [4]
microarray studies (see Additional File 1, Table S5, for the
Table 3: Molecular signatures specifying breast cancer subgroups as defined by hierarchical clustering and Chi2 analysis.
SG1 SG2 SG3 SG5 SG6 SG7 SG9 SG10 SG12
ACADM ERRA BCL2 MTA3 ESR2 ABCC5 BCL2 ABCG2 AKT2
BMI1 IGF1 CCND1 SPP1 IGF1 AKT2 ERBB2 BMI1 CDKN1B
ERRG NCOA3 CDK4 KRT19 AREG GRB7 CDKN1B E4F1
MYC PTGS2 E4F1 MYBL2 EZH2 IRS1 EPHA2 EZH2
RXRA ESR1 HDAC6 NCOA3 ERBB2 HDAC6
GATA3 PRKAR1A PGC1A ERBB4 MAD2L1
GSTP1 SPP1 ESR1 PR
KRT19 GATA3 PRKAR1A
LIV1 GSTP1 PTEN
MAD2L1 IGF1R RXRA
MTA3 IGFBP4
PGC1A LIV1
SERPINB5 PR
TSK/E2IG4 MYBL2
ZNF217 MYC
SERPINB5
TFF1/pS2
These signatures included up-regulated (bold characters) or down-regulated genes as indicated. No specific signature was found concerning 
subgroups 4, 8 and 11, except that a high proportion of tumours from group 4 exhibited the subgroup 3-signature (see Table 4).BMC Cancer 2007, 7:39 http://www.biomedcentral.com/1471-2407/7/39
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list of these tumours). Each tumour in the validation set
was assigned to one of the defined subgroups according to
the highest score obtained by this tumour through the dif-
ferent subgroups. Accordingly, these external tumours
were classified into 7 of the 9 subgroups that were defined
following the Chi2 analysis (Figure 2). Among the 109
tumours used, 76 had been previously classified into the
five reported molecular subtypes (i.e., luminal A, luminal
B, basal-like, ERBB2, and normal-like), while 33 remained
unclassified. As expected, the majority of the ERBB2
tumours (6 out of 8) were classified into subgroup 9,
while the majority of the basal-type tumours (18 out of
20) were classified into subgroup 10. The luminal-type
tumours were dispersed in different groups, confirming
that our set of genes does not allow an optimal clustering
of these tumours. The few normal-like tumours of the val-
idation set were mainly assigned to subgroup 6. Finally,
subgroup 7 apparently gathered together tumours that
were previously classified into different molecular sub-
types.
Bioclinical features of the molecular subtypes
To adress the question of a possible clinical relevance for
our classification, we first focused on the bioclinical fea-
tures of the tumours from the 9 subgroups that were
defined as robust by the Chi2 analysis. As shown in Table
5, subgroup 10 (basal subtype) included 90% of the ER-
tumours with a high histological grade (86% SBRIII). As
expected, the rate of recurrence in this group of tumours
was among the highest (29%). Subgroup 10 (ERBB2 sub-
type) also included high SBR grade tumours (90%
SBRIII), although these were both ER- (50%) and ER+
(50%). Similar observations were recorded, when the clas-
sification of external tumours was considered (Table 6).
Indeed, subgroup 10 (which includes most of the basal-
like tumours) and subgroup 9 (which includes most of
the ERBB2 tumours) both exhibited a bad prognosis (with
rates of recurrence of 57% and 53%, respectively) in agree-
ment with their higher histological grade (80–100%
SBRIII).
Interestingly, the new tumour subclass (i.e. subgroup 7),
which has been defined in this study, exhibited peculiar
clinical features: tumours of this subgroup had mainly an
ER+ status since it included 74% and 82% of the ER+
tumours of the training (Table 5) and validation (Table 6)
sets, respectively; the percentage of pT1 tumours (< 20
mm) was higher in this subgroup than in the respective
overall training (53% vs 29%, p = 0.06, Chi2 test) and val-
idation (82% vs 52%, p = 0.04) cohorts. Finally, despite
the fact that the patients were younger in subgroup 7 than
in the overall training cohort (37% vs 18%, p = 0.06), we
did not detect any recurrence within the 5 year follow-up
(Table 5). Similar trends were observed in the validation
setwith a lower recurrence rate in subgroup 7 than in the
other subgroups (Table 6). To compare the time of recur-
rence between the different subgroups, we used the Kap-
lan-Meier analysis on the training and validation cohorts.
As shown in Figure 3, this analysis emphasized the fact
that tumours of subgroup 7 had one of the best prog-
noses.
Discussion
The 500-gene set, which has been initially used to define
the five to six breast cancer molecular subtypes [2-4], con-
sisted of genes that had a significantly greater variation in
expression between different tumours than between
paired samples from the same tumour. The aim of the
present study was to classify breast tumours on the basis
of the expression of a limited set of genes that have been
selected on the basis of their putative involvement in
tumour sensitivity and/or aggressiveness. We anticipated
Table 4: Percentage of tumours from subgroups 1 to 12 that show the best scores for the respective molecular signatures as defined by 
Chi2 analysis
Subgroups defined by hierarchical clustering
123456789 1 0 1 1 1 2
16 270600060080
2 15 86 42 5 1 40 92 90 01 7 2 9
3 23 14 96 41 050 2 4 00 3 3 0
5 0009 71 21 0 6 0 0 17 14
6 8000 1 4 58 51 20 0 02 9
7 000 1 6 1 4 2 1 86 24 9 13 17 14
9 0003000 1 2 82 080
10 000000009 88 00
12 00000000000 43
Columns represent the different tumour subgroups as defined by Eisen's hierarchical clustering. Rows are related to the distinct molecular 
signatures determined by Chi2. The percentage of tumours from Eisen's subgroups that exhibited proper molecular signatures are highlighted in 
bold. The sum of the % from each column may be higher than 100% as some tumours could exhibit extra signatures. As 41% of tumours from 
subgroup 4 exhibited the molecular signature that specified subgroup 3, tumours from subgroups 3 and 4 were assembled for the rest of the study.BMC Cancer 2007, 7:39 http://www.biomedcentral.com/1471-2407/7/39
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that such a distinct set of genes could cluster tumours in a
different way than that described in the studies by Perou
[2] and Sorlie [3,4], allowing us to define new molecular
subtypes. Our expectation was that such subclasses would
help us define novel phenotypic subsets of breast cancer
with a distinctive clinical outcome. Indeed, the current
taxonomy of breast carcinomas seems insufficient to
allow the classification of all breast tumours. However, a
series of evidences suggests that a molecular classification
of cancers may be a powerful and promising way to over-
come our inability to accurately predict the clinical behav-
iour of breast cancers. Such an approach is expected to
tackle the extreme complexity of the genetic alterations
that are observed in breast cancers. The molecular signa-
tures should, thus, represent a prognostic factor of greater
efficiency than those currently used, such as the lymph
node status, tumour size, hormone-receptor status or his-
tological grade.
The molecular subtypes and gene-signatures reported so
far have been mostly defined via microarrays studies [2-
6,10-12]. Although such an approach allows the most effi-
cient analysis to classify tumors, Q-RT-PCR has some
advantages over microarrays since it provides accurate,
reproducible and sensitive quantification of mRNAs.
Moreover, the quantification of a limited number of genes
avoids the discrepancy due to the restricted number of
samples (tumours) in comparison to the too many varia-
bles (genes), which is a major drawback in the microarray
studies [15]. Moreover, recent reports suggest the possibil-
ity to quantify gene expression using tissue sections from
paraffin-embedded blocks as biological material, predict-
Classification of tumours from an independent validation set according to the molecular signatures that specify the defined sub- groups Figure 2
Classification of tumours from an independent validation set according to the molecular signatures that spec-
ify the defined subgroups. The validation set (109 tumours) included 24 luminal A, 19 luminal B, 5 normal-like, 8 ERBB2, 20 
basal and 33 unclassified tumours. None of the independent tumours were classified into subgroups 5 and 12 as defined by 
hierarchical clustering and Chi2 analysis.
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ing the generalisation of the quantification of RNA expres-
sion in the clinical practice [16,17]. While extensive gene
expression profiling using microarrays is unlikely to
replace the standard immuno-histochemical assessment
in the hospital practice, customized Q-RT-PCR platforms
may represent a more affordable alternative as a clinically
useful assay to identify molecular signatures. Moreover, it
is important to note that a Q-RT-PCR study [18] has
recently confirmed the 70-gene prognosis signature
obtained by van't Veer and collaborators with cDNA
microarrays [10]. Similarly, a real-time Q-RT-PCR assay
has been recently shown to recapitulate the microarray
classification of breast cancers [19]. Also, Q-RT-PCR has
been used to quantify the expression of candidate genes in
breast tumours of patients treated with tamoxifen[16] or
chemotherapy [17].
The 47-gene set used in the present study was largely dis-
tinct from the 500-gene intrinsic subset selected by Perou
et al. [2] and Sorlie et al. [3,4], and had only 15 genes that
overlapped with that. Nevertheless, our minimal set of
genes allowed us to discriminate the basal, ERBB2, nor-
mal-like and luminal subtypes, even though the luminal-
type tumours were not tightly clustered but rather spread
over several groups. Clearly, subgroups 9 (ERBB2 sub-
type) and 10 (basal subtype) were the more robust since
most of the external tumours, which had been previously
classified as ERBB2 and basal subtypes using the 500-gene
intrinsic subset, were now assigned to subgroups 9 and
10, respectively. Indeed, 90% of the external basal-type
tumours were classified into the subgroup 10 and 75% of
the ERBB2 tumours were assigned to the subgroup 9. Sub-
group 6 appeared to have a lower robustness as only 3 out
of 5 of the external normal-like tumours were correctly
classified in this subgroup. However, we would need a
larger number of tumours from this subtype in the valida-
tion set to firmly conclude on the robustness of subgroup
6.
By contrast, our 47-gene set was clearly unable to discrim-
inate between luminal A and luminal B tumours. As a
consequence, tumours from the validation set, that have
been previously identified as luminal A and B tumours,
were not correctly classified in our study. This inadequacy
Table 6: Bioclinical features of the tumours of the validation set forming the molecular subgroups as defined by the Chi2 analysis
Subgroup Number of tumours Hormonal status Age Tumour size Histological grade (SBR) Clinical outcome
n % ER+ % ER- % <50 years % <20 mm % SBRI % SBRII % SBRIII % recurrence
S G 1 7 1 0 0 0 7 1 4 3 07 12 9 4 3
SG2 1 100 0 100 100 0 0 100 0
SG3/4 28 93 7 39 46 18 39 43 46
SG6 18 89 11 67 78 22 39 39 28
SG7 11 82 18 73 82 27 9 64 27
SG9 14 57 43 64 36 0 0 100 57
SG10 30 30 70 70 40 3 17 80 53
Overall cohort 109 70 30 61 52 12 27 61 44
Table 5: Bioclinical features of the tumours of the molecular subgroups as defined by hierarchical clustering and Chi2 analysis
Subgroup Number of 
tumours
Hormonal status Age Tumour size Lymph node status Histological grade (SBR) Clinical 
outcome
n % ER+ % ER- % <50 years % pT1 % pT2-3 % pN0 % pN1 % SBRI % SBRII % SBRIII % recurrence
1 8 88 12 13 38 50 38 50 25 75 0 25
2 12 100 0 8 25 75 67 17 25 58 17 8
3/4 38 95 5 11 21 76 53 42 8 74 16 13
5 5 80 20 0 20 80 60 40 20 80 0 0
6 5 40 60 0 20 80 60 40 40 40 20 20
71 9 7 4 2 6 3 7 5 3 4 2 4 7 4 2 5 3 4 7 0 0
9 10 50 50 10 40 60 50 50 0 10 90 20
10 21 10 90 29 24 71 57 43 5 5 86 29
12 3 100 0 67 0 100 67 33 0 33 67 33
Overall cohort 121 70 30 18 29 68 54 40 18 49 31 15
Only tumours from the Eisen's subgroups, which were correctly classified according to the Chi2 defined molecular signatures, were considered in 
this study (i.e. 121 out of 199). Data related to subgroup 6 did not take into account the normal breast tissues. The sum of the percentages for a 
given subgroup may be less than 100% as tumor size, histological grade or lymph node status were occasionally not determined.BMC Cancer 2007, 7:39 http://www.biomedcentral.com/1471-2407/7/39
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could be due to the weak representation of genes from the
500-gene set in our own 47-gene set, since the use of sets
of genes, which are different from the initial one, has been
previously reported to be less efficient in discriminating
the luminal A and luminal B subtypes [4,6]. Sorlie and
collaborators [4] claimed that their inability to distin-
guish luminal A and luminal B tumours, when using the
West's data set [20], was likely due to the fact that only
half of the genes from their intrinsic gene list were found
in this study. Furthermore, the luminal C subtype, which
was initially reported by Sorlie in an earlier study [3],
could not be reproduced [4] when using a separate 500-
gene set (which had 200 genes in common with the
former 500-gene set). The luminal A/luminal B distinc-
tion seems also less obvious in a recent study [6] that clas-
sified 83 breast tissue samples using a reduced set of
genes, which included 120 genes from the later 500-gene
set [4]. Last but not least, we failed to discriminate the
luminal A/B tumours of the Sorlie's cohort on the basis of
the 15 genes, which are shared by our 47 gene set and the
500-gene set, confirming that the size of the gene-set is
likely to be a critical parameter.
However, our 47-gene set was able to define a new tumour
group (i.e., subgroup 7). This new subclass, which we
found to be relevant after internal and external validation,
was shown to group together tumours with smaller size
and a lower rate of recurrence, although a significant per-
centage of these tumours was ER negative and was from
younger patients. This is true despite the fact that the
training and validation cohorts were clearly distinct, as
tumours studied by van't Veer et al. [10] (the majority of
the tumours of our validation set) were from node-nega-
tive patients that were younger than 55 years and exhib-
ited an overall high rate of recurrence. The fact that
tumours of subgroup 7, from both training and validation
Analysis of the recurrence-free probability in the subgroups defined according to Chi2 molecular signatures Figure 3
Analysis of the recurrence-free probability in the subgroups defined according to Chi2 molecular signatures. A 
Kaplan-Meier analysis was performed on tumours of the training and validation sets that were correctly classified in the indi-
cated molecular subgroups. The p value was calculated by using the log-rank test.
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sets, shared nevertheless some bioclinical features
strengthens the accuracy of our classification with regard
to this new subclass. Noteworthy, the molecular signature
of subgroup 7 might represent a better prognostic factor
than the histological grade, since it allowed low (training
set) as well as high (validation set) SBR grade tumours to
be classified with a better prognosis than the respective
overall cohorts. On the other hand, as the tumours of sub-
group 7 in the validation set were previously classified in
different subtypes, one can hypothesize that these
tumours were not well identified. Obviously, further stud-
ies using larger cohort of patients will be necessary to val-
idate our findings.
In any case, breast cancer taxonomy needs to be improved
and new tumour subclasses have to be defined. Molecular
subtypes and signatures should be subsequently con-
firmed in prospective trials. Indeed, studies like ours do
not consent to discriminate between prospective and pre-
dictive signatures since the majority of the patients receive
adjuvant therapy, which, hopefully, will have an inci-
dence on their clinical outcome. However, once clinically
validated, tumours classifiers based on minimal molecu-
lar signatures should help therapeutic decision-making
and treatment-tailoring for each patient.
Conclusion
By studying the expression of 47 genes selected on the
basis of their potential implication in breast cancer sensi-
tivity, we have classified a cohort of 199 primary breast
tumours into a series of molecular subgroups. The sub-
group 7, which has been highlighted by our study, was
remarkable as it grouped together mainly small ER+
tumours from rather young patients with a low recurrence
rate. Although this finding should be confirmed on a
larger cohort, it suggests that gene expression profiling
using a minimal set of genes may allow the finding of new
breast cancer subclasses with specific bioclinical features.
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